Caresyntax Raises $180 Million Funding to Accelerate Growth and Adoption of Precision Surgery

22-Aug-2024
Computer-generated image

Symbolic image

Caresyntax, a vendor-neutral precision surgery platform, announced raising a total commitment of $180 million through a series C extension and growth debt expansion round.  

Investors in the $180 million round include Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund, and ProAssurance Corp. The financing comprises $80M of equity and up to $100M of growth debt facility.  

Caresyntax is transforming surgery by implementing a scalable, end-to-end software and AI platform. The platform is medical grade, interoperable and allows the capture and use of novel data and applications to enhance surgical precision and patient safety. Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide, delivering automation and actionable insights to hospitals, medical device companies and insurance groups. 

Dennis Kogan, Co-Founder and CEO of Caresyntax: “Together with our partners and investors, we are working towards deploying precision surgical tools, empowered by data and AI, to improve patient outcomes. This financing is not just an investment in Caresyntax, but an investment in the future of surgery. My gratitude extends to our investors who contribute to and believe in the power of smart data and AI usage in the operating room.” 

Since the Company’s 2021 Series C fundraise, Caresyntax has launched innovative AI products which are being leveraged by care teams internationally and opened new markets relating to insurance underwriting and medtech clinical outcome analysis. Today, Caresyntax is focused on leveraging the value of its install base to drive value for the entire surgical ecosystem. 

This funding follows a successful H1 2024 for Caresyntax, marked by over 75% growth in revenue and increased margins, highlighting the expanding recognition and adoption of Caresyntax’s innovative platform in US and EMEA healthcare systems.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.